Headquartered in Hungary, Gedeon Richter is an innovation-driven specialty pharmaceutical company, boasting the biggest pharmaceutical research centre in CEU. One of its latest achievements is the original antipsychotic, cariprazine, already marketed in the US for BD, schizophrenia and aMDD treatment and in most of the EU countries for treatment of schizophrenia in adult patients.